Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.

Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D.

Prostate. 2008 Jun 15;68(9):935-44. doi: 10.1002/pros.20745.

2.

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.

Endocr Relat Cancer. 2005 Dec;12(4):983-98.

3.

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.

Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M.

Prostate. 2008 Jun 15;68(9):965-74. doi: 10.1002/pros.20757.

PMID:
18361408
4.
5.

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.

Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.

Adv Med Sci. 2011;56(2):275-84. doi: 10.2478/v10039-011-0043-x.

PMID:
22037177
7.

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.

Endocr Relat Cancer. 2005 Mar;12(1):119-34.

8.

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.

Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):689-93. doi: 10.3779/j.issn.1009-3419.2012.12.02. Chinese.

9.

1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.

Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD.

Prostate. 2010 Nov 1;70(15):1658-71. doi: 10.1002/pros.21201.

10.

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.

J Cell Physiol. 2006 May;207(2):420-7.

PMID:
16419029
11.

Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.

Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.

J Hematol Oncol. 2012 Jul 11;5:16. doi: 10.1186/1756-8722-5-16.

12.

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C, Bologna M.

Thromb Haemost. 2005 May;93(5):964-75.

PMID:
15886816
13.

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.

Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.

Prostate. 2004 Feb 15;58(3):259-68.

PMID:
14743465
14.

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.

Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.

15.

Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.

Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG.

Cancer Res. 2008 Oct 1;68(19):8004-13. doi: 10.1158/0008-5472.CAN-08-0280.

16.

Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.

Li P, Zhang Q, Torossian A, Li ZB, Xu WC, Lu B, Fu S.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e391-7. doi: 10.1016/j.ijrobp.2011.12.090. Epub 2012 Mar 11.

PMID:
22414288
17.

[Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].

Zhang XJ, Zhang L, Liu YP, Xu HM, Sun P, Song JG, Luo YH.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):181-6. doi: 10.3760/cma.j.issn.0253-3766.2013.03.005. Chinese.

PMID:
23879997
18.
19.

Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.

Carrión-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A.

Int J Oncol. 2012 Sep;41(3):1128-38. doi: 10.3892/ijo.2012.1509. Epub 2012 Jun 6.

PMID:
22684500
20.

Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.

Sos ML, Zander T, Thomas RK, Staratschek-Jox A, Claasen J, Wolf J.

J Thorac Oncol. 2008 Feb;3(2):170-3. doi: 10.1097/JTO.0b013e3181622c05.

Supplemental Content

Support Center